|Bid||15.80 x 0|
|Ask||15.90 x 0|
|Day's range||15.75 - 15.91|
|52-week range||10.78 - 16.04|
|Beta (3Y monthly)||0.35|
|PE ratio (TTM)||68.28|
|Forward dividend & yield||0.18 (1.16%)|
|1y target est||12.61|
NEW YORK, Dec. 07, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Post the acquisition, Propeller will continue to operate as an independent entity within ResMed's (RMD) Respiratory Care suite.
Dual-listed sleep device manufacturer ResMed is spending $US225 million on asthma and pulmonary specialist Propeller Health.
With a market capitalization of US$16b, ResMed Inc (NYSE:RMD) is a large-cap stock, which is considered by most investors as a safe bet. Common characteristics for these big stocks are Read More...
Post culmination of the transaction, MatrixCare will continue to operate as a standalone business within ResMed's (RMD) SaaS portfolio.
Corporate Travel Management Ltd (ASX:CTD), Graincorp Ltd (ASX:GNC), and Santos Ltd (ASX:STO) shares will be on watch on Thursday. Here's why...
Mick Farrell has been the CEO of ResMed Inc (NYSE:RMD) since 2013. First, this article will compare CEO compensation with compensation at other large companies. Next, we’ll consider growth that Read More...
MatrixCare consolidation is expected to enhance ResMed's (RMD) capacity to improve patient transitions of care as well as its provider skills.
Beach Energy Ltd (ASX:BPT), Commonwealth Bank of Australia (ASX:CBA), Santos Ltd (ASX:STO) shares will be on watch on the ASX 200 on Wednesday. Here's what you need to know...
Healthcare star ResMed Inc. (ASX:RMD) has announced a US$750 million SaaS acquisition. Should you buy shares?
Dual-listed sleep apnea equipment developer ResMed is set to buy US health software company MatrixCare for $US750 million ($A1.04bn).
NEW YORK, Oct. 30, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
ResMed (RMD) delivered earnings and revenue surprises of 1.25% and 2.02%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?